Eli Lilly Stock Rises as GLP-1 Demand Drives Beat-and-Raise

LLY will snap a five-day losing streak if gains hold

Laura McCandless

Deputy Editor

Aug 5, 2026 at 9:21 AM

Eli Lilly (NYSE:LLY) is higher ahead of the open, up 4.8% to trade at $1,169, after the pharmaceutical giant reported second-quarter earnings and revenue that topped Wall Street's expectations, while raising its full-year 2026 revenue guidance. Demand for blockbuster weight-loss drug Zepbound and diabetes treatment Mounjaro continued to drive growth.

The shares have seen some volatility since their record high of $1,249.45 on July 7. If these early gains hold, LLY will snap a five-day losing streak. Despite the recent weakness, the stock remains up 45.1% over the last 12 months and has added 3.8% in 2026.

Options traders, meanwhile, have been much more bearish than usual. LLY's 10-day put/call volume ratio of 1.74 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) ranks higher than 98% of annual readings, signaling unusually heavy put buying.

Follow @Schaeffers

The $25K Day Trading Barrier is Gone

The long-standing Pattern Day Trader (PDT) rule that required many traders to maintain a $25,000 account balance is no longer standing in the way.

That means more traders can actively pursue short-term opportunities without the barrier that kept so many on the sidelines.

Now it's all about having the right strategy.

Dynamite Day Trading Signals helps you hit the ground running with up 2 options trade alerts per week, built to capture fast-moving opportunities.

👉 Sign up now to receive the next trade